RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. حسب Xiaojuan Li (351842)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. حسب Rodrigo Ibarra-García-Padilla (19697623)

Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data حسب E.J. Martins (7141313)

Diverse stress conditions trigger a rapid and dramatic decrease in miR-520b-3p and a corresponding increase in ATF5 mRNA over time in HeLa cells. حسب Kari A. Gaither (9046190)

Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR. حسب Jordan A. Gunning (18143970)

Full-length PRR expression increases and sPRR secretion decreases in the absence of PACE4 in mouse. حسب Amro H. Mohammad (15081540)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. حسب Martin Selinger (3195987)

Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. حسب Martin Selinger (3195987)

"…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …"

Effects of SNPs on the Protein Stability, Increasing or Decreasing. حسب Mirza Jawad Ul Hasnain (8351388)

Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome. حسب Jennifer Gribble (10005444)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات: